Eisai and Purdue Pharma have announced six-month results from the SUNRISE 2 Phase III clinical study evaluating the efficacy and safety of lemborexant.
Eisai has kicked off a mid-stage study assessing its potential first-in-class experimental therapy lemborexant in Alzheimer’s patients with Irregular Sleep-Wake Rhythm Disorder (ISWRD).